Back to top
more

CRISPR Therapeutics (CRSP)

(Delayed Data from NSDQ)

$56.09 USD

56.09
2,988,903

-0.17 (-0.30%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $56.05 -0.04 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

New Strong Sell Stocks for August 1st

by Zacks Equity Research

CRSP, CSTL and SIGI have been added to the Zacks Rank #5 (Strong Sell) List on August 1, 2025.

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know

by Zacks Equity Research

In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $56.26, indicating a -2.46% shift from the previous trading day.

Ekta Bagri headshot

3 Genomics Stocks Worth Adding to Your Portfolio in 2025

by Ekta Bagri

CRISPR-based innovators like NTLA, EDIT and PRME are gaining traction as genomics reshapes the future of medicine and biotech

Zacks Equity Research

Should You Invest in CRISPR Therapeutics (CRSP) Based on Bullish Wall Street Views?

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in CRISPR Therapeutics (CRSP). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Zacks Equity Research

Will Beam Therapeutics Inc. (BEAM) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

Beam Therapeutics (BEAM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Vertex Gears Up to Report Q2 Earnings: Is a Beat in the Cards?

by Zacks Equity Research

VRTX eyes second-quarter growth with surging Trikafta sales. Investors' focus is likely to be on the progress of Casgevy, and Alyftrek and Journavx launches.

Zacks Equity Research

New Strong Sell Stocks for July 29th

by Zacks Equity Research

BUR, CRSP and CNL have been added to the Zacks Rank #5 (Strong Sell) List on July 29, 2025.

Zacks Equity Research

CRISPR Therapeutics to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

CRSP investors await the company's Q2 results with a focus on Casgevy sales growth and updates on gene-editing pipeline progress.

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

CRISPR Therapeutics (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) concluded the recent trading session at $64.76, signifying a -1.97% move from its prior day's close.

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $66.06, moving 3.05% from the previous trading session.

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors

by Zacks Equity Research

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $52.73, denoting a -6.54% move from the preceding trading day.

Zacks Equity Research

Is It Worth Investing in CRISPR Therapeutics (CRSP) Based on Wall Street's Bullish Views?

by Zacks Equity Research

The average brokerage recommendation (ABR) for CRISPR Therapeutics (CRSP) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Sweta Killa headshot

Innovation ETF (ARKK) Hits New 52-Week High

by Sweta Killa

Cathie Wood's ARKK hits a 52-week high after bold biotech moves, signaling renewed momentum in disruptive tech.

Zacks Equity Research

Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader Market

by Zacks Equity Research

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $51.19, representing a -1.88% change from its previous close.

Zacks Equity Research

Intellia Gains 29.8% in a Month: How Should You Play the Stock?

by Zacks Equity Research

NTLA stock surges 29.8% in a month, driven by gene therapy pipeline progress and growing investor attention.

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Kinjel Shah headshot

Vertex Down Around 9% in Three Months: Should You Buy, Sell or Hold the Stock?

by Kinjel Shah

VRTX slips 9% in three months on slow new drug uptake and pipeline hiccups, but CF strength and 2025 growth offer a reason to hold.

Zacks Equity Research

Is CRISPR Therapeutics (CRSP) a Buy as Wall Street Analysts Look Optimistic?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), CRISPR Therapeutics (CRSP) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) Stock Moves 1.88%: What You Should Know

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $47.66, moving +1.88% from the previous trading session.

Sundeep Ganoria headshot

CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?

by Sundeep Ganoria

CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains.

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing

by Zacks Equity Research

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $46.78, marking a +2.7% move from the previous day.

Sundeep Ganoria headshot

Can Casgevy Deliver a Turnaround for CRISPR Therapeutics?

by Sundeep Ganoria

CRSP bets on Casgevy to drive growth, but its extremely high price tag and slow rollout test investor patience in a crowded field.